Back to search

Article

Biweekly CAPOX versus Triweekly CAPOX in the adjuvant therapy of post-surgery CRC: a randomized controlled trial

2023-06-26

Abstract excerpt

<h4>Background: </h4> Adjuvant CAPOX (capecitabine plus oxaliplatin) provided significant disease-free survival (DFS) benefit in patients with high-risk stage II or stage III colorectal cancer (CRC). Conventional triweekly CAPOX results in 14-38% 3-4 grade hematological toxicity. Modified biweekly CAPOX was observed to be generally well-tolerated in previous studies. <h4>Methods: </h4>: High-risk stage II and sta...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cf808cd0-0f02-5b51-9cf2-6bfee6608b18
DOI
10.21203/rs.3.rs-2823745/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Biweekly CAPOX versus Triweekly CAPOX in the adjuvant therapy of post-surgery CRC: a randomized controlled trialDOI 10.21203/rs.3.rs-2823745/v1
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.Semantic proximity
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.Semantic proximity
Does capecitabine maintenance therapy versus active monitoring confer a survival benefit after first-line treatment of metastatic colorectal cancer? A meta-analysis of randomized controlled trialsSemantic proximity
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.Semantic proximity
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.Semantic proximity
Evaluation of Postoperative Chemotherapy Duration of Capecitabine-Alone Regimen for Surgery Treated Elderly Colon Cancer Patients : A Cohort StudySemantic proximity
Anlotinib maintenance following adjuvant chemotherapy in newly diagnosed stage III–IV patients with epithelial ovarian cancer: a retrospective studySemantic proximity
Rare but Marvelous Efficacy of Neoadjuvant Chemotherapy for Adenocarcinoma of Rectum: A Case ReportSemantic proximity
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.Semantic proximity
A Four Ingredients Chinese Herbal Formula, Decreases the Metastatic Recurrence of Postoperative Patients With Stage II- III Colorectal CancerSemantic proximity
Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic FactorsSemantic proximity
Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world studySemantic proximity
Select a neighboring publication to make it the new centre.